Skip to Content

Zealand Pharma A/S ZLDPF

Morningstar Rating
$135.00 +0.62 (0.46%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ZLDPF is trading at a 684% premium.
Price
$134.40
Fair Value
$87.31
Uncertainty
Very High
1-Star Price
$285.67
5-Star Price
$43.11
Economic Moat
Dftfzf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZLDPF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$134.38
Day Range
$133.93135.00
52-Week Range
$33.42140.28
Bid/Ask
$135.00 / $136.75
Market Cap
$9.54 Bil
Volume/Avg
371 / 1,983

Key Statistics

Price/Earnings (Normalized)
Price/Sales
158.61
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
270

Comparables

Valuation

Metric
ZLDPF
BIVI
MORF
Price/Earnings (Normalized)
Price/Book Value
20.391.414.21
Price/Sales
158.61
Price/Cash Flow
Price/Earnings
ZLDPF
BIVI
MORF

Financial Strength

Metric
ZLDPF
BIVI
MORF
Quick Ratio
7.632.4337.20
Current Ratio
12.302.4538.17
Interest Coverage
−44.02−9.50
Quick Ratio
ZLDPF
BIVI
MORF

Profitability

Metric
ZLDPF
BIVI
MORF
Return on Assets (Normalized)
−21.29%−115.58%−18.85%
Return on Equity (Normalized)
−27.41%−256.00%−19.43%
Return on Invested Capital (Normalized)
−26.07%−130.07%−23.26%
Return on Assets
ZLDPF
BIVI
MORF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
DsvlwshsqvNzxr$625.5 Bil
Vertex Pharmaceuticals Inc
VRTX
QcdjbcgXqmncsv$127.0 Bil
Regeneron Pharmaceuticals Inc
REGN
PgnxbdzmNlvzv$119.0 Bil
Moderna Inc
MRNA
HfkslbzbBwbc$47.1 Bil
Alnylam Pharmaceuticals Inc
ALNY
NjgpjfxYcqfb$33.0 Bil
argenx SE ADR
ARGX
SnrpkzxSysq$27.7 Bil
BioNTech SE ADR
BNTX
ZssdzfjxGmgc$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
SsflgzhhCgspcwv$15.9 Bil
United Therapeutics Corp
UTHR
BhrmstnhpSzwb$14.4 Bil
Incyte Corp
INCY
VrjmvwmdWjdfbb$12.3 Bil

Sponsor Center